Digital medicine adoption, also referred to as digital therapeutics, was challenging ahead of the pandemic. Clinical validation and FDA clearances have gradually moved the needle on how these treatments are perceived. But the need for remote patient monitoring for chronic conditions during the Covid-19 pandemic has led to increased interest in this area with the hope that it will continue to climb beyond the pandemic.
Many of the digital medicines available are aimed at addressing behavioral health needs. The social isolation associated with the Covid-19 pandemic exacerbated or led to stress, depression, anxiety and substance misuse.
The future of digital medicines is just one of the panel discussions that will be offered at MedCity INVEST PharmaTech, a virtual conference scheduled for July 26. It will bring together technology disruptors, Big Pharma and biotech leaders, investors and entrepreneurs to discuss how to adopt digital strategies to transform every aspect of the pharma industry.
To register free of charge, click here.
The landscape of digital medicines holds great promise. A new generation of companies is aiming to transform the digital therapeutics market. Learn from experts in the field of pharma, digital health and commercialization.
Among the speakers on the panel are:
- Lana Ghanem, Managing Director, Hikma Ventures
- Pierre Leurent, President, Digital Health, Aptar Pharma
- Abhishek Shah, Co-founder & CEO, Wellthy Therapeutics
The panel discussions will conclude with a startup pitch contest. The theme of this mini Pitch Perfect is reinventing clinical trials. The application deadline is May 31. To apply, click here.
To apply to be a speaker at INVEST PharmaTech, follow this link. The deadline to apply is May 26.
For information to sponsor the conference from a panel discussion to a video spotlight, email: [email protected]
Photo: Who_I_am, Getty Images
